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Objectives To investigate symptoms and self-reported 
health of patients conservatively treated for aortic stenosis 
(AS) and to identify factors associated with treatment 
decision and patient outcomes.
Design A cross-sectional survey with an 18-month 
follow-up.
setting One tertiary university hospital in Western 
Norway.
Participants In all, 1436 patients were diagnosed with 
AS between 2000 and 2012, and those 245 still under 
conservative treatment in 2013 were included in this 
study.
Primary and secondary outcome measures Primary 
outcome measures were symptoms and self-reported 
health status. Secondary outcomes were treatment 
decision and patient survival after 18 months.
results A total of 136 patients with mean (SD) age 79 
(12) years, 52% men responded. Among conservatively 
treated patients 77% were symptomatic. The symptom 
most frequently experienced was dyspnoea. Symptomatic 
patients reported worse physical and mental health 
compared with asymptomatic patients (effect size 
1.24 and 0.74, respectively). In addition, symptomatic 
patients reported significantly higher levels of anxiety 
and depression compared with asymptomatic patients. 
However, symptom status did not correlate with 
haemodynamic severity of AS. After 18 months, 117 
(86%) were still alive, 20% had undergone surgical 
aortic valve replacement (AVR) and 7% transcatheter 
aortic valve implantation (TAVI). When adjusting for age, 
gender, symptomatic status, severity of AS and European 
system for cardiac operative risk evaluation (EuroSCORE), 
patients with severe AS had more than sixfold chance 
of being scheduled for AVR or TAVI compared with 
those with moderate AS (HR 6.3, 95% CI 1.9 to 21.2, 
p=0.003). Patients with EuroSCORE ≥11 had less chance 
for undergoing AVR or TAVI compared with those with 
EuroSCORE ≤5 (HR 0.06, 95% CI 0.01 to 0.46, p=0.007).
Conclusions Symptoms affected both physical and 
mental health in conservatively treated patients with 
AS. Many patients with symptomatic severe AS are not 
scheduled for surgery, despite the recommendations in 
current guidelines. The referral practice for AVR is a path 
for further investigation.
IntrODuCtIOn
Aortic stenosis (AS) is the most common 
heart valve disease in the Western world 
causing significant morbidity and mortality. 
As a result of an ageing population, the 
prevalence of AS is increasing.1 AS is most 
commonly caused by a degenerative calcifi-
cation process leading to leaflet immobility, 
which in turn causes impaired blood flow 
through the heart and symptoms of pres-
sure overload.2 The three cardinal symptoms 
strengths and limitations of this study
 ► The study is targeting an understudied group of 
patients as very few studies have investigated self-
reported health in patients with aortic stenosis (AS) 
under conservative treatment.
 ► The study employs standardised and validated 
questionnaires.
 ► Patient-reported outcomes are important to inform 
health professionals as well as policymakers in 
order to improve the quality of care to patients with 
AS.
 ► Patients were diagnosed with AS 1–11 years before 
the survey.
 ► The study is limited by the moderate response rate, 
and that it was carried out as a single-centre study.
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of AS, indicating the need for clinical intervention, are 
breathlessness, chest pain and dizziness or syncope.1 An 
unknown proportion of patients remains asymptomatic 
for several years despite the presence of haemodynami-
cally severe disease.3 Symptomatic AS has been associated 
with a sharp increase in death risk with an estimated 
50% death rate at 2 years unless aortic valve replacement 
(AVR) is performed.3 While much is known about the 
pathophysiology of AS, little is known about the disease 
burden placed on patients’ daily life, whether symptom-
atic or asymptomatic.4
Current European guidelines recommend AVR for 
patients with a class I assessment. These are patients who 
are symptomatic with severe AS, asymptomatic patients 
with severe systolic dysfunction or patients offered AVR 
as a concomitant procedure during another primary 
open cardiac surgery indication.5 Despite these recom-
mendations, studies have documented poor adherence 
to evidence-based guidelines, as 33%–60% of the patients 
with severe symptomatic AS are inappropriately excluded 
from AVR.6 Hence, there seems to be a gap between 
what is recommended and the real clinical practice. For 
various reasons, there are a large percentage of suitable 
candidates that are currently not referred for AVR.5 7 
Further, transcatheter aortic valve implantation (TAVI) 
has become widely accepted as an alternative to AVR and 
medical therapy for patients at high surgical risk.5
There are some reports on patient-reported outcomes 
in individuals with AS before and after AVR or TAVI.8 
However, few studies have focused on the quality of life or 
self-reported health status of symptomatic or asymptom-
atic patients with AS who receive conservative treatment 
(ie, medical therapy) and in whom surgical intervention 
is postponed or declined either by the heart team or by 
the patient.4 9
The aims of this study were to investigate symptoms and 
self-reported health of patients conservatively treated for 
AS and to identify factors associated with treatment deci-
sion and patient outcomes.
MethODs
Study design and participants
A cross-sectional design was used to investigate factors 
related to patient-reported health status and the impact 
of valve disease on the patients’ daily life. Patients 
were followed up for 18 months after the survey. Study 
endpoints were having undergone TAVI or AVR or 
all-cause death.
In April 2013, a postal questionnaire was sent along 
with a prestamped return envelope to 1436 patients ≥18 
years of age, able to write and understand Norwegian 
and diagnosed with AS in a tertiary university hospital 
in Western Norway. Results from the patients that had 
undergone AVR (n=1191) are reported elsewhere.10 
Two hundred and forty-five patients diagnosed with AS 
between 2000 and 2012 and still under conservative 
treatment were included in this study. To be included, 
candidate participants had to have echocardiographi-
cally verified AS in the native aortic valve, with at least a 
maximum transvalvular gradient of ≥40 mm Hg. Severe 
AS was defined according to current guidelines.5 Patients 
had to fulfil at least one of the following haemodynamic 
criteria: an aortic valve area (AVA) <1 cm2; mean pressure 
gradient >40 mm Hg or peak aortic jet velocity >4 m/s, as 
demonstrated by Doppler echocardiography. Moderate 
AS was defined as having an AVA of 1.5–1.0 cm2, a mean 
pressure gradient of 25–40 mm Hg or a peak aortic jet 
velocity of 3.0–4.0 m/s.5
Data collection
Hospital information system registries and patient 
medical records were used to identify patients eligible for 
the study and to exclude patients with a maximum aortic 
gradient of less than 40 mm Hg, or patients who were 
cognitively impaired or deceased. Sociodemographic 
variables, smoking status, symptoms, comorbidities and 
physical and mental health status were obtained by means 
of patient self-reports. Clinical variables such as date of AS 
diagnosis, reasons for declining an AVR or TAVI, results 
from Doppler echocardiography examination regarding 
severity of AS and aortic regurgitation, treatment modal-
ities, and survival were retrieved from patient medical 
records. Expected operative risk was calculated using 
numeric and logistic European system for cardiac oper-
ative risk evaluation (EuroSCORE) I classification (www. 
euroscore. org).
self-reported health status and symptoms
Measurement of self-reported health status was obtained 
using the Short Form 12 (SF-12) health questionnaire.11 
SF-12 has been used to assess health status in patients 
with AS undergoing AVR or TAVI.12 The SF-12 (standard 
V.1.0) questionnaire consists of 12 items. The first ques-
tion asks the patient to rate his/her health as excellent, 
very good, good, fair or poor. In the survival analysis for 
the present study, the response categories ‘excellent’ and 
‘very good’ and ‘fair’ and ‘poor’ were merged. SF-12 has 
two summary measures: a physical component summary 
(PCS) and a mental component summary (MCS).11 Each 
component summary results in a score ranging from 0 
to 100. Summary scores are then standardised to a mean 
of 50 and a SD of 10. Higher scores represent better-per-
ceived health status. Internal reliability (Cronbach’s α) 
was 0.89 and 0.88 for PSC and MSC, respectively.
To evaluate the burden of symptoms related to dyspnoea 
or heart failure, the Minnesota Living with Heart Failure 
Questionnaire (MLHFQ) was used. MLHFQ is a widely 
used disease-specific tool with well-documented validity, 
reliability and sensitivity for symptoms related to heart 
failure.13 14 All of the symptoms listed on the MLHFQ are 
also symptoms that may occur in individuals with AS.15 
Health impairment is evaluated using a six-point scale, 
ranging from 0 (no impact) to 5 (severe impact). The 
instrument produces a total score (21 items; range 0–105); 
a physical dimension subscore (PDS) (eight items; range 
group.bmj.com on March 6, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
 3Oterhals K, et al. BMJ Open 2017;7:e016489. doi:10.1136/bmjopen-2017-016489
Open Access
0–40) and an emotional dimension subscore (EDS) (five 
items; range 0–25). Lower scores indicate better health. 
For MLHFQ, Cronbach’s α was 0.94 for PDS and 0.88 for 
EDS.
The categories of symptomatic or asymptomatic AS 
were determined by patients’ self-report in the survey. 
Symptoms of angina were obtained using a single ques-
tion: “Have you had chest pain (yes/no)?” One question 
from the MLHFQ was used to determine the proportion 
of patients with dyspnoea: “Did your heart failure prevent 
you from living as you wanted during the last month by 
making you short of breath?” Possible answers ranged 
from 0 (no impact) to 5 (severe impact). Response values 
of ≥2 were categorised as symptomatic. Dizziness/syncope 
was assessed by the question: “How much has dizziness/
syncope influenced your daily activities the last 4 weeks?” 
Possible responses were: 1 (not at all), 2 (a little), 3 
(some), 4 (much) and 5 (very much). Response values 
of 3–5 were categorised as symptomatic. Cut-off points 
were set to avoid including patients who experienced very 
little discomfort as symptomatic. Timing of symptoms for 
valve replacement was not a goal in this cross-sectional 
study of symptomatic and asymptomatic patients with AS 
and their subsequent prognosis. Hence, patients were not 
assessed repeatedly for study purposes.
The Hospital Anxiety and Depression Scale (HADS) 
was used to assess possible symptoms of anxiety or 
depression.16 HADS consists of a seven-item subscale for 
anxiety (HADS-A) and a seven-item subscale for depres-
sion (HADS-D). For all items, responses are scored on 
a four-category scale, with 0 representing no symptoms 
and 3 representing maximum symptoms. The scores on 
each subscale range from 0 to 21. For identifying possible 
cases of anxiety and depressive disorders, the HADS has 
an optimal cut-off score of at least 8 for both subscales.16 
The Cronbach’s α value was 0.86 for HADS-A and 0.75 
for HADS-D.
The New York Heart Association (NYHA) Functional 
Classification was used to describe the impact of the 
disease on daily activities.17 NYHA classifies patients into 
four categories (I–IV), with higher classes indicating 
more severe symptoms and limitations in physical activity. 
The self-assessed NYHA classification tool asks patients 
to assign themselves to a NYHA class by ticking one of 
four boxes indicating categories that best describe their 
ability to perform physical activity. This tool is a well-docu-
mented and valid method of assessing symptoms of heart 
failure.17
ethics
The present study was conducted in accordance with 
the ethical guidelines contained in the World Medical 
Association’s Declaration of Helsinki (2004) and was 
approved by the Regional Medical Ethics Committee of 
Western Norway (number 2010/01954). Information 
about the study, the possibility of withdrawing at any time 
and confidentiality issues were included in the letter that 
accompanied the questionnaire. Informed consent was 
taken as a patient returning the completed question-
naire. In accordance with the regional ethical committee, 
patients who failed to respond via mail were contacted 
once over telephone in order to encourage them to 
complete the questionnaire.
statistical analysis
Descriptive statistics for continuous variables are 
presented as means and SDs. For comparisons between 
groups, the unpaired t-test was used. Descriptive statis-
tics for categorical variables are presented as counts and 
proportions, and comparisons done using the exact χ2 test. 
Correlation between continuous variables was estimated 
by Pearson’s correlation (r). Kaplan-Meier analysis was 
used to assess patient survival and cumulative incidence 
of AVR/TAVI after 18 months. Cox regression analysis 
was used to evaluate time-related events and their associ-
ations with baseline characteristics, such as age, gender, 
symptomatic status, severity of AS and EuroSCORE based 
on clinical experience and previous research.6 Results are 
reported as HRs and 95% CIs. No imputing of missing 
data was performed.
The statistical analyses were performed using SPSS for 
Windows V.22 (IBM), STATA/SE V.14.0 for Windows 
(February 2015), Matlab V.9.0 (The MathWorks, 2016) 
and Venn Diagram Plotter (http:// omics. pnl. gov/ soft-
ware/ venn- diagram- plotter). A two-sided p value ≤0.05 
was considered statistically significant. To evaluate the 
clinical importance of differences in self-reported phys-
ical and mental health of symptomatic and asymptomatic 
patients, we computed effect sizes (ESs statistics) by 
dividing the mean differences in scores by the SD of the 
norm data.18 To interpret the ES, we followed the sugges-
tion of Cohen, and regarded ESs of 0.2–0.5 as small, 
0.5–0.8 as moderate and 0.8 and above as large.18
results
Patients’ characteristics, symptoms and health status
Of the 245 patients treated conservatively and not having 
undergone AVR or TAVI by April 2013, 137 patients 
(56%) returned the questionnaire. One patient was 
excluded from further analysis due to a congenital subval-
vular AS (figure 1). No statistically significant differences 
were found between responders and non-responders with 
respect to age (p=0.157) or gender (p=0.062).
The mean (SD) age was 79 (12) years and 52% were 
men. One hundred and five (77%) patients were symp-
tomatic. The most frequently self-reported symptom was 
dyspnoea, 57 (71%); followed by chest pain 49 (61%) 
and dizziness/syncope 26 (33%). Overlapping symptoms 
are shown in figure 2. Patients with symptomatic AS were 
older, had attained a lower educational level, were more 
often living alone, were placed in a higher NYHA class, 
had a higher EuroSCORE I and were more often on medi-
cation such as beta-blockers and statins, as compared with 
asymptomatic patients (table 1).
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Of the 136 patients, 22 (16%) were not accepted for 
AVR by the heart team, while 12 (9%) patients declined 
AVR by themselves. The remaining 102 (75%) were 
considered as potential surgical candidates and remained 
under medical observation. The distribution of AS 
severity, symptomatic status and treatment decision at 
baseline are shown in figure 1. No gender differences 
were found for severity of AS, chest pain, dyspnoea, dizzi-
ness/syncope or numbers of symptoms reported. Risk 
stratification of all 136 patients revealed that 29 patients 
(21%) had a numeric EuroSCORE ≤5, 81 (60%) had a 
EuroSCORE between 6 and 10 and 26 (19%) had a Euro-
SCORE of 11–15.
Patients with asymptomatic AS reported better physical 
and mental health status compared with symptomatic 
patients. The estimated ES for the differences in SF-12 
measures between symptomatic and asymptomatic 
patients was 1.24 for the PCS and 0.74 for the MCS. The 
assessment of the impact of AS on the patients’ daily life 
(MLHFQ) showed that it had a significantly larger impact 
in symptomatic patients. In addition, asymptomatic 
patients had significantly lower HADS scores compared 
with symptomatic patients (table 2).
eighteen months follow-up
Eighteen months after the survey, of the 136 patients, 117 
(86%) were still alive, Of whom 22 (16%) had undergone 
isolated AVR, including 5 with AVR in combination with 
coronary artery bypass grafting and 10 (7%) had under-
gone TAVI. Nineteen patients (14%) had died; whereas 1 
died 6 days after AVR. The flow chart of patient outcomes 
(survival and AVR/TAVI) within the 18 months follow-up 
is shown in figure 1.
Among the 102 individuals with medical observa-
tion at the time of the survey (figure 3), 22 (21%) had 
undergone AVR, 7 (7%) had TAVI and 9 (9%) had died. 
Additionally, two patients were scheduled for AVR and 
two for TAVI during follow-up. Among the 22 patients 
Figure 1 Flow chart showing patient with and without AVR participating in the study, and outcomes after 18 months follow-
up for 136 patients aged 35 to 95 years under conservative treatment at the time of survey. Patients were diagnosed between 
the years 2000 and 2012 and were invited to complete the questionnaire in year 2013. AS, aortic stenosis; AVR, aortic valve 
replacement; TAVI, transcatheter aortic valve implantation.
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previously declined from AVR by the heart team, 3 (14%) 
had undergone TAVI and 5 (23%) had died. Four of the 
12 patients who decided to receive conservative treatment 
had died and none had undergone AVR or TAVI.
Of the 20 patients with asymptomatic severe AS 
(table 1), only 3 (15%) had undergone an exercise test. 
One of them had a rise in blood pressure and a decrease 
of 2 mm in the ST-segment on EKG, but no symptoms 
of angina. He was finally accepted for surgery, but died 
before the operation. In the other two cases, the patients 
experienced a slight rise in pulse, but in both cases the 
test ended prematurely due to limb fatigue.
After 18 months, of the 81 patients with symptomatic 
severe AS at baseline, 31 had still not undergone surgical 
treatment, and five had died prior to the end of the study. 
Of the latter, one had been accepted for AVR and one 
for TAVI. The remaining 26 patients were still treated 
conservatively after 18 months, either due to symptoms 
unrelated to AS (n=3), patients’ decision (n=1), hori-
zontal aortic root not eligible for TAVI (n=1), Alzheimer 
disease (n=1) or vague symptoms (n=3). The remaining 
17 patients had, for unknown reasons, not been referred 
for cardiac surgery. Seven of the 20 patients with asymp-
tomatic severe AS at baseline were treated with AVR (n=5) 
or TAVI (n=2) within 18 months. All of them developed 
symptoms, mainly dyspnoea before the intervention.
Multiple Cox regression analysis for selection of AVR 
or TAVI was performed and included age, gender, symp-
tomatic status, severity of AS and EuroSCORE as variables 
(figure 4). Patients with severe AS had more than sixfold 
chance of being scheduled for AVR or TAVI compared 
with those with moderate AS (HR 6.3, 95% CI 1.9 to 21.2, 
p=0.003). EuroSCORE ≥11 decreased the chance for 
undergoing AVR or TAVI compared with having Euro-
SCORE ≤5 (HR 0.06, 95% CI 0.01 to 0.458, p=0.007).
Self-rated general health at baseline tended to 
predict event-free survival (figure 5A), and EuroSCORE 
tended to predict overall survival (figure 5B) by the 
18 months follow-up, but the results were not statistically 
significant.
DIsCussIOn
In the present study, the relationship between patient-re-
ported outcomes and the severity of AS was investigated 
by employing well-established health status instruments. 
The results revealed that symptoms had a larger influ-
ence on the conservatively treated patients’ physical and 
mental health than the severity of AS. AS severity alone, 
as measured by Doppler echocardiography examinations, 
did not differ between symptomatic and asymptomatic 
patients.
Figure 2 Number of symptomatic patients with aortic stenosis with overlapping symptoms (n=105). A, chest pain; B, 
dyspnoea; C, dizziness/syncope. 
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Table 1 Baseline characteristics of 136 patients aged 35 to 95 years diagnosed with severe-to-moderate aortic stenosis in 





(n=105) Asymptomatic (n=31) p Value*
Basic characteristics
Age in years; mean (SD) (range) 79 (11) (35–95) 80 (10) 75 (12) 0.025
Gender, men, n (%) 70 (52) 55 (52) 15 (48) 0.696
Living alone, n (%) 51 (38) 44 (42) 7 (23) 0.052
Education, n (%) 0.037
   Elementary school 73 (54) 62 (60) 11 (36)
   High school 33 (24) 23 (22) 10 (32)
   University/college 29 (22) 19 (18) 10 (32)
Smoking, n (%) 0.121
   Current smoker 11 (8) 9 (9) 2 (7)
   Previous smoker 58 (43) 49 (47) 9 (30)
   Never smoked 66 (49) 47 (45) 19 (63)
Sa-NYHA, mean (SD) 2.18 (0.87) 2.34 (0.88) 1.66 (0.55) <0.001
   NYHA I, n (%) 25 (19) 14 (14) 11 (40)
   NYHA II, n (%) 70 (53) 53 (52) 17 (57)
   NYHA III, n (%) 22 (17) 21 (21) 1 (3)
   NYHA IV, n (%) 14 (11) 14 (14) 0 (0)
Doppler echocardiography examination†
  Ejection fraction (%), mean (SD) 59 (9) 58 (10) 60 (7) 0.304
  V-max (m/s), mean (SD) 4.0 (0.7) 4.0 (0.7) 3.9 (0.4) 0.418
  AVA (cm2/BSA), mean (SD) 0.54 (0.2) 0.53 (0.2) 0.57 (0.2) 0.257
  Mean aortic gradient, mean (SD) 41 (15) 42 (15) 38 (11) 0.115
Severity of AS 0.159
   Severe AS, n (%) 101 (74) 81 (80)‡ 20 (20)‡
   Moderate AS, n (%) 35 (26) 24 (65)‡ 11 (35)‡
Aortic regurgitation, n (%) 0.067
   Mild (1/4) 55 (40) 43 (41) 19 (18)
   Moderate (2/4) 27 (20) 19 (18) 8 (25)
   Moderate-to-severe (3/4) 2 (1.5) 0 (0) 2 (6)
  EuroSCORE-log, mean (SD) 12.8 (11.6) 13.9 (11.8) 9.0 (10.3) 0.027
  EuroSCORE-numeric, mean (SD) 8.0 (3.1) 8.3 (3.1) 6.9 (2.8) 0.022
  Years since diagnosis, mean (SD) 5.7 (3.2) 5.5 (3.1) 6.3 (3.5) 0.207
Medical history, n (%)
  Diuretics 34 (25) 30 (29) 4 (13) 0.078
  Beta-blockers 87 (64) 71 (68) 16 (52) 0.104
  Statins 80 (59) 67 (64) 13 (42) 0.030
  Myocardial infarction 24 (18) 18 (20) 6 (18) 0.753
  Stroke 19 (14) 16 (16) 3 (10) 0.394
  AF intermittent 33 (28) 28 (32) 5 (17) 0.140
  AF permanent 8 (7) 7 (7) 1 (3) 0.454
  COPD 8 (6) 8 (8) 0 (0) 0.109
  Arthritis 25 (19) 22 (22) 3 (10) 0.139
  Osteoporosis 18 (14) 15 (15) 3 (0) 0.454
Continued
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Previous studies have shown that important outcomes 
such as symptoms, function and well-being are weakly 
associated with objective measures of disease severity.19 It 
is known that the degree of AS at the onset of symptoms 
differs among patients.3 The symptom most frequently 
experienced by patients in this study was dyspnoea. 
Dyspnoea was also the most frequent symptom observed 
in patients selected for AVR or TAVI. Since the presence 
of dyspnoea predicts worse survival for patients with AS,20 
our treatment algorithm is well supported by clinical 
outcome studies20 and guidelines.5 In the present study, 
mild symptoms of shortness of breath were classified as 
asymptomatic AS. Surprisingly, nearly 60% of the asymp-
tomatic patients classified themselves within NYHA class 
II, indicating they experienced shortness of breath or 
tiredness, or palpitations when performing strenuous 
activities. Rather than attributing these two symptoms 
solely to exercise induced AS another plausible explana-
tion is the presence of other comorbidities, advanced age 
or their generally poor physical condition.
Symptomatic and asymptomatic patients also differed 
in physical and mental health status, with the latter having 
better scores. As the ES showed, this difference is also 
clinically relevant.18 Although neither the Doppler echo-
cardiogram measurements (ie, AS severity) nor number 
of comorbidities differed between the two groups, the 
analyses showed that patient-reported outcomes did 
differ. This is in line with the reports of van Geldorp et al, 
who concluded that even minor AS symptoms may have 
a major impact on patients’ physical and mental well-
being, as well as quality of life.4 They also concluded that 
there was no relationship between stenosis severity and 
patients’ physical or mental health, but symptoms severity 
according to NYHA classification corresponded well with 
the SF-36 scores.
Patients who graded their general health as fair or poor 
tended to have a lower 18-month event-free survival, as 
compared with those grading their health as good or 
better, but the difference was not statistically significant. 
Self-rated health has been shown to predict mortality 
1 year after TAVI.21
In the present study, symptomatic patients reported 
significantly higher levels of both anxiety and depres-
sion compared with asymptomatic patients, indicating 
that AS symptoms have a great impact on mental health. 





(n=105) Asymptomatic (n=31) p Value*
  Cancer 26 (20) 21 (21) 5 (16) 0.539
  PCI 18 (13) 14 (13) 4 (13)
  Previous CABG 6 (4) 6 (6) 0 (0) 0.336
  Pacemaker 10 (8) 7 (7) 3 (10) 0.555
*Tests comparing symptomatic versus asymptomatic (bold p values denote significance at p<0.05).
†Figures are mean values for moderate and severe stenosis.
‡Symptomatic or asymptomatic patients are % of all patients with severe or moderate AS.
AF, atrial fibrillation; AS, aortic stenosis; AVA, aortic valve area; BSA, body surface area; CABG, coronary artery bypass grafting; COPD, 
chronic obstructive pulmonary disease; EuroSCORE, European system for cardiac operative risk evaluation; NYHA, New York Heart 
Association; Sa-NYHA, self-assessed New York Heart Association functional classification; V-max, maximum jet velocity; PCI, percutanous 
coronary intervention.
Table 1 Continued 
Table 2 Baseline self-reported health status of 136 patients aged 35 to 95 years diagnosed with aortic stenosis in the period 








SF-12, PCS, mean (SD) 36.8 (11.7) 33.8 (11) 46.2 (9) <0.001
SF-12, MCS, mean (SD) 52.3 (10.4) 50.6 (11) 58.0 (4) <0.001
MLHFQ Physical mean (SD) 11.8 (11.3) 14.9 (11) 3.3 (5) <0.001
MLHFQ Emotional mean (SD) 3.1 (5.1) 3.9 (6) 0.6 (2) <0.001
HADS-A, mean (SD) 3.9 (3.4) 4.2 (4) 2.9 (2) 0.036
HADS-D, mean (SD) 4.5 (3.4) 5.0 (4) 2.7 (2) <0.001
HADS-A >8, n (%) 18 (14) 17 (17) 1 (3) 0.071
HADS-D >8, n (%) 24 (18) 22 (22) 2 (7) 0.056
HADS-A, Hospital Anxiety and Depression Scale—anxiety component; HADS-D, Hospital Anxiety and Depression Scale—depression 
component; MCS, mental component summary of SF-12; MLHFQ, Minnesota Living with Heart Failure Questionnaire; PCS, physical 
component summary of SF-12; SF-12, Short Form 12.
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AVR responding to the same questionnaire,10 conserva-
tively treated symptomatic patients in the present study 
reported a higher level of anxiety and depression. This 
supports the findings that AS symptoms have a negative 
impact on patients’ mental health, suggesting that valve 
surgery can reduce this mental burden.
In symptomatic patients with severe AS, aortic valve 
surgery is generally recommended both by European and 
American guidelines.5 22 Fifty-five per cent of the patients 
who fulfilled the criteria for receiving AVR, either were 
not on the waiting list for AVR or had been treated with 
AVR or TAVI within 18 months after the survey. The low 
proportion of asymptomatic patient with AS who under-
went exercise testing may suggest that the indication for 
surgery was underestimated. Symptomatic status can be 
difficult to determine, especially in elderly patients, as 
they tend to minimise or deny symptoms, or effectively 
reduce their physical activity level to avoid symptoms.23 
One-third of the patients who report to be asymptom-
atic develop symptoms during exercise testing; thus, this 
type of testing is recommended to unmask symptoms in 
patients with severe AS.24 With appropriate supervision 
and monitoring, symptom-limited stress testing is safe 
in severe AS and can add important prognostic value 
especially in older people that might have problems 
performing a treadmill exercise test due to coexisting 
morbidities.24
A possible explanation why many patients are not 
referred for surgery despite severe symptomatic AS, is that 
the patients are discharged from the university hospital 
without being implemented into a treatment algorithm 
provided for the local hospitals, cardiologists in private 
practice or general practitioners. Multidisciplinary heart 
teams, together with the patients and their family, should 
conclude with either conservative treatment, AVR or TAVI 
according to current guidelines, shared decision-making, 
comorbidities and operative risks. Although the majority 
of the patients declined for surgery at baseline had a Euro-
SCORE of >10, a high EuroSCORE did not fully explain 
why some patients still were not referred for surgery. As 
EuroSCORE is known to overestimate the risk of postop-
erative mortality, especially in low-risk patients scheduled 
for isolated AVR, the postoperative mortality risk may 
have been overestimated in some of the patients.25
AS severity and not symptomatic status, predicted selec-
tion for surgical treatment in this cohort. The gap between 
the existing guidelines and their actual application has 
been demonstrated in previous studies.5 7 Close follow-up 
Figure 3 Reasons for not having undergone aortic valve replacement (AVR) at baseline in 136 patients with symptomatic and 
asymptomatic severe-to-moderate aortic stenosis (AS).
Figure 4 Cumulative occurrence of aortic valve replacement (AVR) or transcatheter aortic valve implantation (TAVI) from Cox 
model, according to European system for cardiac operative risk evaluation (EuroSCORE) range (likelihood ratio p value (LR-
p)=0.011) in patients with aortic stenosis within 18 months adjusted for gender (LR-p=0.336), age (LR-p=0.223), symptomatic 
status (LR-p=0.437) and severity of aortic stenosis (LR-p=0.002).
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of the asymptomatic patients is also important, as severe 
symptoms or cardiac death may occur suddenly.26 There 
is robust evidence that AVR prolongs life in patients with 
symptomatic and severe AS. This is regardless of severity 
of symptoms or the response to medical treatment.3 It 
is also of utmost importance that health professionals 
inform patients with AS to contact their physician as soon 
as symptoms occur and close follow-up of asymptomatic 
patients is recommended.27 The optimal time for inter-
vention is still open to debate.27 Some argue that early 
elective surgery in asymptomatic patients with severe 
AS might be worthwhile, since rapid deterioration is 
associated with the disease.26 Early surgery in patients 
with severe asymptomatic AS has also shown to improve 
long-term survival by decreasing cardiac mortality28 as 
well as lower 5-year incidences of all cause death and 
heart failure hospitalisation compared with conservative 
treated patients.29 In addition, an ongoing prospective 
multicentre randomised controlled trial (the AVATAR 
trail) is testing the hypothesis that elective AVR is superior 
to medical treatment until symptom onset in asymptom-
atic patients with isolated severe AVR and normal LVEF.30
study strengths and limitations
Very few studies have investigated self-reported health in 
patients with AS under conservative treatment. Patient-re-
ported outcomes are important to inform health 
professionals as well as policy-makers in order to improve 
the quality of care to patients with AS. Thus, the present 
study has some methodological limitations. It was carried 
out as a single-centre study, which may decrease the gener-
alisability of the results. The sample, however, represents 
patients from both densely populated and rural areas. 
Another limitation is the retrospective design of the study 
and that we gathered only limited data prospectively. 
Further, a potential limitation is the moderate response 
rate of 56%. A possible reason for this response rate can 
be that some of the patients were still asymptomatic, and 
perhaps not motivated to take the time to answer the 
questionnaire. Alternatively, patients with severe disease 
burden were incapable of completing the questionnaire.
COnClusIOns
Patients receiving conservative treatment for AS are an 
understudied group of patients with cardiac problems. 
The present study demonstrated that AS symptoms have 
great impact on patients’ physical and mental health 
status. However, this impact does not reflect the severity 
of AS. Still, many patients with symptomatic severe AS 
are not scheduled for surgery, despite the recommen-
dations in current guidelines. Our results indicate that 
the referral practice for aortic valve surgery ought to be 
carefully scrutinised. Further well-designed prospective 
studies are needed to fully understand the disease burden 
of AS and to optimise the timing of surgical intervention. 
Self-reported health status may be a valuable supplement 
to physical examination during the clinical evaluation of 
high-risk patients with AS.
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